Company intelligence / Profile preview

Clever Leaves

Ownership: Public · CLVR
Employees: ~296
Development stage: Commercial

Overview

Clever Leaves produces EU-GMP certified medicinal cannabis flower and extracts for global B2B customers. The company has shipped to over fifteen countries, holds EU-GMP certification for both API and finished product forms, and supports clinical research initiatives such as Project Change Lives to advance scientific understanding of cannabinoids

Therapeutic areas: OtherNeurology
Modalities: Small molecule (cannabinoids, THC, CBD isolates and extracts)Plant-derived therapy
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

cannabidiol

Commercial

Indications: Various medical conditions

Partnerships

CansativaBiopharmaceutical Research CompanyCannatrek & Institute of Drug Technology IDT Australia

Beyond the preview

Go deeper on Clever Leaves.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clever Leaves.

Explore the full profile